Verastem, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
VSTM Nasdaq 2830 www.verastem.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Verastem, Inc.

Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026 - Jul 23rd, 2026 5:30 am
Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer - Jul 22nd, 2026 2:01 pm
RBC Capital Reaffirms Outperform Rating For Verastem (VSTM) - Jul 15th, 2026 9:43 am
Verastem (VSTM) Surges 6.3%: Is This an Indication of Further Gains? - Jul 10th, 2026 3:45 am
Here’s What RBC Capital Has to Say About Verastem (VSTM) - Jul 3rd, 2026 7:13 am
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jul 2nd, 2026 2:30 pm
Verastem (VSTM) Shares Encouraging Results from VS-7375 Phase 1/2 Trial - Jun 30th, 2026 10:34 am
Is Verastem, Inc. (VSTM)’s KRAS-Targeted Combination Therapy a Breakthrough for Pancreatic Cancer? - Jun 25th, 2026 6:42 am
Verastem Says VS-7375 Trial Data Shows Anti-Tumor Activity in Advanced Solid Tumors - Jun 23rd, 2026 2:44 pm
VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors - Jun 23rd, 2026 2:01 pm
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer - Jun 17th, 2026 5:30 am
Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer - Jun 16th, 2026 2:01 pm
Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program - Jun 15th, 2026 2:01 pm
VSTM Stock Climbs After-Hours As FDA Grants Fast Track To Lung Cancer Drug — Retail Eyes The Next Keytruda - Jun 3rd, 2026 6:10 pm
Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer - Jun 3rd, 2026 2:01 pm
Verastem (VSTM) Loses 34.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - May 18th, 2026 7:35 am
Verastem, Inc. (NASDAQ:VSTM) Just Released Its First-Quarter Earnings: Here's What Analysts Think - May 11th, 2026 7:02 am
Verastem Q1 Earnings Call Highlights - May 9th, 2026 1:10 am
Verastem (VSTM) Q1 2026 Earnings Transcript - May 8th, 2026 9:46 am
Verastem, Inc. Q1 2026 Earnings Call Summary - May 8th, 2026 6:30 am